Trial Profile
A 12-week, randomized, double-blind, placebo-controlled, parallel-group. fixed-dosage study to evaluate the efficacy and safety of armodafinil (50, 150, and 250 mg/day) as treatment for patients with excessive sleepiness associated with mild or moderate closed traumatic brain injury.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Armodafinil (Primary)
- Indications Sleep disorders
- Focus Therapeutic Use
- Sponsors Cephalon
- 02 Apr 2022 This trial has been completed in France (Date of the global end of the trial : 06-Jan-2011), according to European Clinical Trials Database record.
- 20 Jun 2011 New trial record